Prevention of Obesity and Insulin Resistance in Mice Lacking Plasminogen Activator Inhibitor 1
Overview
Authors
Affiliations
Increased plasminogen activator inhibitor 1 (PAI-1) has been linked to not only thrombosis and fibrosis but also to obesity and insulin resistance. Increased PAI-1 levels have been presumed to be consequent to obesity. We investigated the interrelationships of PAI-1, obesity, and insulin resistance in a high-fat/high-carbohydrate (HF) diet-induced obesity model in wild-type (WT) and PAI-1-deficient mice (PAI-1(-/-)). Obesity and insulin resistance developing in WT mice on an HF diet were completely prevented in mice lacking PAI-1. PAI-1(-/-) mice on an HF diet had increased resting metabolic rates and total energy expenditure compared with WT mice, along with a marked increase in uncoupling protein 3 mRNA expression in skeletal muscle, likely mechanisms contributing to the prevention of obesity. In addition, insulin sensitivity was enhanced significantly in PAI-1(-/-) mice on an HF diet, as shown by euglycemic-hyperinsulinemic clamp studies. Peroxisome proliferator-activated receptor (PPAR)-gamma and adiponectin mRNA, key control molecules in lipid metabolism and insulin sensitivity, were maintained in response to an HF diet in white adipose tissue in PAI-1(-/-) mice, contrasting with downregulation in WT mice. This maintenance of PPAR-gamma and adiponectin may also contribute to the observed maintenance of body weight and insulin sensitivity in PAI-1(-/-) mice. Treatment in WT mice on an HF diet with the angiotensin type 1 receptor antagonist to downregulate PAI-1 indeed inhibited PAI-1 increases and ameliorated diet-induced obesity, hyperglycemia, and hyperinsulinemia. PAI-1 deficiency also enhanced basal and insulin-stimulated glucose uptake in adipose cells in vitro. Our data suggest that PAI-1 may not merely increase in response to obesity and insulin resistance, but may have a direct causal role in obesity and insulin resistance. Inhibition of PAI-1 might provide a novel anti-obesity and anti-insulin resistance treatment.
Elevated levels of PAI-1 precede the occurrence of type 2 diabetes mellitus.
Hernestal-Boman J, Ohman T, Jansson J, Lind M, Rolandsson O, Bergdahl I Diabetol Metab Syndr. 2025; 17(1):61.
PMID: 39966987 PMC: 11834294. DOI: 10.1186/s13098-025-01629-4.
Biagioli M, Fiorucci S Liver Res. 2025; 5(3):119-141.
PMID: 39957845 PMC: 11791866. DOI: 10.1016/j.livres.2021.08.003.
Safa , Norton C Pharmaceuticals (Basel). 2024; 17(9).
PMID: 39338372 PMC: 11434643. DOI: 10.3390/ph17091210.
Inter-Organ Communication Involved in Brown Adipose Tissue Thermogenesis.
Takahashi K, Yamada T, Katagiri H Adv Exp Med Biol. 2024; 1461:161-175.
PMID: 39289280 DOI: 10.1007/978-981-97-4584-5_11.
Xu Z, Huang Y Sci Rep. 2024; 14(1):21207.
PMID: 39261530 PMC: 11391048. DOI: 10.1038/s41598-024-71908-z.